Definium Therapeutics, Inc. (NASDAQ: DFTX) is a Healthcare company (Biotechnology) with a market capitalization of $4.0B. The Maz Rating grades it against the other companies in its sector.
Definium Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $29.38, Definium Therapeutics, Inc. trades at 4.1x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -54.0%, return on invested capital of -25.2% and a free cash flow yield of -4.7%. On the balance sheet: a debt-to-equity ratio of 0.04 and a current ratio of 15.53. Over the past 52 weeks the share price ranged from $12.88 to $49.20, with a beta of 2.21.
Definium Therapeutics, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 12 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Definium Therapeutics, Inc. (DFTX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.86% / 30% · (Cash+Inv) / Mkt Cap (36m) 24.7% / 30% · Interest income / Revenue 1013900000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.86% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 24.7% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 1013900000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.86% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 24.7% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 1013900000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 2.41% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 96.3% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 1013900000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 3.41% / 33.33% · (Cash+ST Inv) / Total Assets 97.4% / 33.33% · (Cash+Recv) / Total Assets 97.4% / 33.33% · Interest income / Revenue 1013900000.0% / 5% | Fail |
No. As of September 2026, Definium Therapeutics, Inc. (DFTX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Definium Therapeutics, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 1013900000.0% of each dividend: Definium Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.